EUVIMEDEUVIMED entdecken
Crossref

Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?

Alexandra Porlier, Pierre-Yves Gagnon, Valérie Chénard, Marc Veillette, Nicolas Bertrand, Caroline Duchaine, Natalie J Michael, Chantale Simard, Benoit Drolet

Journal of Pharmaceutical Sciences · 2023

DOI: 10.1016/j.xphs.2023.06.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2023. Verfasst von Alexandra Porlier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (CRIUCPQ-UL), Québec QC, Canada. Hauptthemen laut MEDLINE: Drug Packaging, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Durvalumab is a monoclonal antibody approved for the treatment of lung, urothelial and biliary tract cancers. Durvalumab is supplied in vials as a solution containing no preservatives. Monographs recommend single use of durvalumab vials, and that any leftovers be discarded within 24 h. Thus, significant portions of unused product from opened vials are wasted on a daily basis, generating considerable financial losses. The objective of the present study was to assess the physicochemical and microbiological stability of durvalumab vials kept at 4 °C or room temperature, at 7 and 14 days after opening. Following pH and osmolality measurements, turbidity and submicronic aggregation of durvalumab solution were evaluated by spectrophotometry and dynamic light scattering, respectively. Moreover, steric exclusion high performance liquid chromatography (SE-HPLC), ion exchange HPLC (IEX-HPLC) and peptide mapping HPLC were used to respectively assess aggregation/fragmentation, charge distribution and primary structure of durvalumab. Microbiological stability of durvalumab was evaluated by incubation of vial leftovers on blood agar. All experiments showed physicochemical and microbiological stability of durvalumab vial leftovers for at least 14 days when aseptically handled and kept at either 4 °C or at room temperature. These results suggest the possible extension of utilization of durvalumab vial leftovers well beyond 24 h.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug PackagingAntibodies, MonoclonalSpectrophotometryGlassDrug StabilityDrug Storage

Stichwörter der Autor:innen

DurvalumabMicrobiological stabilityPhysicochemical stabilityVial leftovers

Substanzen

durvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (CRIUCPQ-UL), Québec QC, Canada.
  • Département de pharmacie de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL), Québec QC, Canada.
  • Centre de recherche du CHU de Québec Université Laval, Québec QC, Canada.
  • Centre de recherche du CHU de Québec Université Laval, Québec QC, Canada; Faculté de pharmacie, Université Laval, Québec QC, Canada.
  • Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (CRIUCPQ-UL), Québec QC, Canada; Faculté des sciences et de génie, Département de biochimie, de microbiologie…
  • Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (CRIUCPQ-UL), Québec QC, Canada; Faculté de pharmacie, Université Laval, Québec QC, Canada.

Zitieren

APA

Porlier, A., Gagnon, P. Y., Chénard, V., Veillette, M., Bertrand, N., Duchaine, C., Michael, N. J., Simard, C., & Drolet, B. (2023). Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2023.06.014

Vancouver

Porlier A, Gagnon PY, Chénard V, Veillette M, Bertrand N, Duchaine C, et al. Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?. Journal of Pharmaceutical Sciences. 2023. doi:10.1016/j.xphs.2023.06.014

BibTeX
@article{Porlier2023,
  author = {Porlier, Alexandra and Gagnon, Pierre-Yves and Chénard, Valérie and Veillette, Marc and Bertrand, Nicolas and Duchaine, Caroline and Michael, Natalie J and Simard, Chantale and Drolet, Benoit},
  title = {Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2023},
  doi = {10.1016/j.xphs.2023.06.014}
}
Kostenlos starten →